Edgar Filing: ANI PHARMACEUTICALS INC - Form 4

		-	-								
ANI PHAR Form 4 January 06,	MACEUTICALS 2014	INC									
FORM						NCE C			PPROVAL		
	UNITED	STATES S	ECURITIES . Washingtor			NGE CO	OMMISSION	OMB Number:	3235-0287		
Check the			vv asiningtoi	I, D.C. 20	542			Expires:	January 31,		
if no lon subject t Section Form 4 o	51AIEN 16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
Form 5 obligation may con <i>See</i> Instr 1(b).	tinue. Section 17	20(h) of the Invictment Comment A of (1040)									
(Print or Type	Responses)										
4			2. Issuel I talle und Tiener of Trading				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (-	. Date of Earliest 7	Francastion			X Director	10%	Owner		
C/O ANI P	HARMACEUTIC	CALS, 0	Month/Day/Year) 1/02/2014	Tansaction			XOfficer (give below)		er (specify		
	(Street)		. If Amendment, E iled(Month/Day/Ye	-	1		6. Individual or Jo Applicable Line) _X_ Form filed by O	one Reporting Pe	erson		
BAUDETT	Ъ. MN 56623						Form filed by M Person	ore than One Re	porting		
(City)	(State)	(Zip)	Table I - Non-	Derivative	Secur	rities Acqu	iired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)		tion Date 2A. Deemed ay/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired (A Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A)			Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common			Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)			
Stock, par value \$0.0001	01/02/2014		A <u>(1)</u>	12,139	А	<u>(1)</u>	129,049	D			
Common Stock, par value \$0.0001	01/02/2014		F <u>(2)</u>	5,644	D	\$ 19.412 (2)	123,405	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: ANI PHARMACEUTICALS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Tit	le and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onNumber	Expiration D	ate	Amou	unt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Unde	rlying	Security	Secu
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e		Secur	rities	(Instr. 5)	Bene
	Derivative				Securities			(Instr	. 3 and 4)		Owne
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date	Expiration	T . 1	or		
						Exercisable	Date	Title	Number		
					(\mathbf{A}) (\mathbf{D})				of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
PRZYBYL ARTHUR C/O ANI PHARMACEUTICALS, INC. 210 MAIN STREET WEST BAUDETTE, MN 56623	Х		President and CEO				
Signatures							
/s/ Jane A. Meyer, as attorney in fact	01/06/20	14					
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents a portion of the shares to be received by the Reporting Person under a Transaction Bonus Agreement with ANIP Acquisition Company, which portion was released to the Reporting Person from a rabbi trust on the date indicated.

Represents sales effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 12, 2013, the proceeds of which are used to pay the required tax withholding amount on the shares released from the rabbi trust. The price reported in Column 4 is a

(2) weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.24 to \$19.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by him at each separate price on each date of sale.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: ANI PHARMACEUTICALS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.